Non-Invasive Prenatal Testing Market Report by Product Type, Test Type, Technology, Method, Application, End-User, and Region 2024-2032
세계의 비침습적 출생 전 검사 시장 규모는 2023년 40억 달러에 달했습니다. 향후 IMARC Group은 시장이 2032년까지 140억 달러에 이르며 2024-2032년 사이에 14.6%의 성장률(CAGR)을 나타낼 것으로 예측했습니다.
비침습적 출생 전 검사(NIPT)는 태아의 이상의 존재를 검출하기 위해 임산부의 혈액 샘플에서 수행되는 출생 전 스크리닝의 형태입니다. 이 검사는 주로 어머니의 혈액에서 DNA 단편을 분석하여 다운 증후군(또는 Trisomy 21), 에드워드 증후군(또는 Trisomy 18), 파타우 증후군(또는 Trisomy 13), 터너 증후군과 같은 유전성 질환 을 진단하는 데 사용됩니다. 이 방법은 융모막 융모 샘플링(CVS)과 같은 다양한 불안정하고 침습적인 치료의 필요성을 없애고 임신 9주 이후에 수행 할 수 있습니다.
태아 유전 질환의 유병률 증가는 시장 성장을 가속하는 주요 요인 중 하나입니다. 또한 생명과학 및 의료 산업 부문에서의 기술 발전도 시장을 뒷받침하고 있습니다. 예를 들어, DNA 시퀀싱 기술의 개발, 재생 의학, 분자 연구의 획기적인 발전은 모든 심각한 질병의 가능성을 미숙한 단계에서 극복하는 엄청난 잠재력을 창출합니다. 게다가 출생 전 검사의 수용률 증가, 건강 의식 증가, 대중들 사이에서 이러한 검사의 장점과 의의에 대한 인식도 시장 성장의 원동력이 되고 있습니다. 이분 척추, 구개열, 겸상 적혈구 빈혈을 포함한 다른 유전 질환을 진단하고 태아 발달의 초기 단계에서 치료하는 대체 수단을 임산부뿐만 아니라 의료 제공업체도 채용하고 있습니다. 게다가 어머니의 고령 출산(35세 이상)으로의 동향 변화도 시장 성장에 긍정적인 영향을 미칩니다. 모체 연령의 상승은 고혈압, 생식 능력 감소, 유산 위험, 태아의 염색체 이상 위험 증가 등 많은 건강 합병증을 유발할 수 있습니다.
이 보고서에서 다루는 주요 질문
- 2023년 세계의 비침습적 산전 검사시장 규모는?
- 2024-2032년 세계의 비침습적 산전 검사 시장의 예상 성장률은?
- 세계의 비침습적 산전 검사시장을 견인하는 주요인은?
- 세계의 비침습적 산전 검사 시장의 제품 유형별 내역은?
- 세계의 비침습적 산전 검사 시장의 검사 유형별 내역은?
- 세계의 비침습적 산전 검사 시장의 기술별 내역은?
- 세계의 비침습적 산전 검사 시장의 방법별 내역은?
- 세계의 비침습적 산전 검사 시장의 용도별 내역은?
- 세계의 비침습적 산전 검사 시장의 최종 사용자별 내역은?
- 세계의 비침습적 산전 검사 시장의 주요기업/참가기업은?
목차
제1장 서문
제2장 조사 범위와 조사 방법
- 조사의 목적
- 이해관계자
- 데이터 소스
- 시장 추정
- 조사 방법
제3장 주요 요약
제4장 소개
제5장 세계의 비침습적 출생 전 검사 시장
- 시장 개요
- 시장 실적
- COVID-19의 영향
- 시장 예측
제6장 시장 내역: 제품 유형별
제7장 시장 내역 : 검사 유형별
- Materni 21
- Harmony
- Panaroma
- Verifi
- NIFTY
- 기타
제8장 시장 분석 : 기술별
제9장 시장 분석 : 방법별
- 초음파 검출
- 생화학 스크리닝 검사
- 모체 혈장에서의 세포 유리 DNA 검사
- 모체 혈액에서의 태아 세포 검사
- 기타
제10장 시장 분석: 용도별
제11장 시장 내역: 최종 사용자별
제12장 시장 분석: 지역별
- 북미
- 아시아태평양
- 유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인
- 러시아
- 기타
- 라틴아메리카
- 중동 및 아프리카
제13장 SWOT 분석
제14장 밸류체인 분석
제15장 Porter's Five Forces 분석
- 개요
- 구매자의 협상력
- 공급기업의 협상력
- 경쟁도
- 신규 진입업자의 위협
- 대체품의 위협
제16장 경쟁 구도
- 시장 구조
- 주요 기업
- 주요 기업 프로파일
- Agilent Technologies, Inc.
- Berry Genetics Inc.
- BGI Genomics Co. Ltd.
- Eurofins Scientific Services Limited
- F. Hoffmann-La Roche Ltd
- GE Healthcare
- Igenomix
- Illumina Inc.
- Laboratory Corporation
- Natera Inc.
- Perkinelmer Inc.
- Thermo Fisher Scientific Inc.
- Yourgene Health plc
JHS
The global non-invasive prenatal testing market size reached US$ 4.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 14.0 Billion by 2032, exhibiting a growth rate (CAGR) of 14.6% during 2024-2032.
Non-invasive prenatal testing (NIPT) is a form of prenatal screening conducted on a pregnant woman's blood sample to detect the presence of fetal abnormalities. The test is primarily used to diagnose genetic disorders such as Down syndrome (or trisomy 21), Edwards syndrome (or trisomy 18), Patau syndrome (or trisomy 13) and Turner syndrome, by analyzing DNA fragments in the mother's blood. The procedure eliminates the need for various precarious and invasive procedures, such as chorionic villus sampling (CVS) and can be performed after nine weeks of pregnancy.
The growing prevalence of genetic disorders of the fetus is one of the key factors driving the market growth. Furthermore, technological advancements in the field of life sciences and healthcare industry is also providing a boost to the market. For instance, the development of DNA sequencing technologies, regenerative medicines and breakthroughs in molecular research have created immense possibilities to combat the chances of any serious disease at the primitive stage itself. Additionally, the increasing acceptance rate for prenatal testing, along with rising health consciousness and awareness regarding the benefits and significance of such testing among the masses, is also driving the market growth. Healthcare providers, as well as expecting parents, are adopting alternatives to diagnose other genetic disorders, including spina bifida, cleft palate, and sickle cell anemia, and treat them in the early stages of fetal development. Moreover, the shifting trend toward childbearing at high maternal age (35 years or older) is also positively impacting the market growth. Advancing maternal age can lead to numerous health complications, such as high blood pressure, reduced fertility, risk of miscarriage and increased risk of chromosomal anomalies in the fetus.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global non-invasive prenatal testing market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product type, test type, technology, method, application and end-user.
Breakup by Product Type:
Consumables
Instruments
Breakup by Test Type:
Materni 21
Harmony
Panaroma
Verifi
NIFTY
Others
Breakup by Technology:
NGS
WGS
Others
Breakup by Method:
Ultrasound Detection
Biochemical Screening Tests
Cell-Free DNA in Maternal Plasma Tests
Fetal Cells in Maternal Blood Tests
Others
Breakup by Application:
Trisomy
Microdeletion Syndrome
Others
Breakup by End-User:
Hospitals
Diagnostic Laboratories
Others
Breakup by Region:
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The report has also analysed the competitive landscape of the market with some of the top non invasive prenatal testing companies key players being Agilent Technologies, Inc., Berry Genetics, Inc., BGI Genomics Co., Ltd., Eurofins Scientific Services Limited, F. Hoffmann-La Roche Ltd, GE Healthcare, Igenomix, Illumina Inc., Laboratory Corporation, Natera Inc., PerkinElmer Inc., Thermo Fisher Scientific Inc., and Yourgene Health plc.
Key Questions Answered in This Report
- 1. What was the size of the global non-invasive prenatal testing market in 2023?
- 2. What is the expected growth rate of the global non-invasive prenatal testing market during 2024-2032?
- 3. What are the key factors driving the global non-invasive prenatal testing market?
- 4. What has been the impact of COVID-19 on the global non-invasive prenatal testing market?
- 5. What is the breakup of the global non-invasive prenatal testing market based on the product type?
- 6. What is the breakup of the global non-invasive prenatal testing market based on the test type?
- 7. What is the breakup of the global non-invasive prenatal testing market based on the technology?
- 8. What is the breakup of the global non-invasive prenatal testing market based on the method?
- 9. What is the breakup of the global non-invasive prenatal testing market based on the application?
- 10. What is the breakup of the global non-invasive prenatal testing market based on the end-user?
- 11. What are the key regions in the global non-invasive prenatal testing market?
- 12. Who are the key companies/players in the global non-invasive prenatal testing market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Non-Invasive Prenatal Testing Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Product Type
- 6.1 Consumables
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Instruments
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
7 Market Breakup by Test Type
- 7.1 Materni 21
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Harmony
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Panaroma
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Verifi
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
- 7.5 NIFTY
- 7.5.1 Market Trends
- 7.5.2 Market Forecast
- 7.6 Others
- 7.6.1 Market Trends
- 7.6.2 Market Forecast
8 Market Breakup by Technology
- 8.1 NGS
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 WGS
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Others
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
9 Market Breakup by Method
- 9.1 Ultrasound Detection
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
- 9.2 Biochemical Screening Tests
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
- 9.3 Cell-Free DNA in Maternal Plasma Tests
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
- 9.4 Fetal Cells in Maternal Blood Tests
- 9.4.1 Market Trends
- 9.4.2 Market Forecast
- 9.5 Others
- 9.5.1 Market Trends
- 9.5.2 Market Forecast
10 Market Breakup by Application
- 10.1 Trisomy
- 10.1.1 Market Trends
- 10.1.2 Market Forecast
- 10.2 Microdeletion Syndrome
- 10.2.1 Market Trends
- 10.2.2 Market Forecast
- 10.3 Others
- 10.3.1 Market Trends
- 10.3.2 Market Forecast
11 Market Breakup by End-User
- 11.1 Hospitals
- 11.1.1 Market Trends
- 11.1.2 Market Forecast
- 11.2 Diagnostic Laboratories
- 11.2.1 Market Trends
- 11.2.2 Market Forecast
- 11.3 Others
- 11.3.1 Market Trends
- 11.3.2 Market Forecast
12 Market Breakup by Region
- 12.1 North America
- 12.1.1 United States
- 12.1.1.1 Market Trends
- 12.1.1.2 Market Forecast
- 12.1.2 Canada
- 12.1.2.1 Market Trends
- 12.1.2.2 Market Forecast
- 12.2 Asia Pacific
- 12.2.1 China
- 12.2.1.1 Market Trends
- 12.2.1.2 Market Forecast
- 12.2.2 Japan
- 12.2.2.1 Market Trends
- 12.2.2.2 Market Forecast
- 12.2.3 India
- 12.2.3.1 Market Trends
- 12.2.3.2 Market Forecast
- 12.2.4 South Korea
- 12.2.4.1 Market Trends
- 12.2.4.2 Market Forecast
- 12.2.5 Australia
- 12.2.5.1 Market Trends
- 12.2.5.2 Market Forecast
- 12.2.6 Indonesia
- 12.2.6.1 Market Trends
- 12.2.6.2 Market Forecast
- 12.2.7 Others
- 12.2.7.1 Market Trends
- 12.2.7.2 Market Forecast
- 12.3 Europe
- 12.3.1 Germany
- 12.3.1.1 Market Trends
- 12.3.1.2 Market Forecast
- 12.3.2 France
- 12.3.2.1 Market Trends
- 12.3.2.2 Market Forecast
- 12.3.3 United Kingdom
- 12.3.3.1 Market Trends
- 12.3.3.2 Market Forecast
- 12.3.4 Italy
- 12.3.4.1 Market Trends
- 12.3.4.2 Market Forecast
- 12.3.5 Spain
- 12.3.5.1 Market Trends
- 12.3.5.2 Market Forecast
- 12.3.6 Russia
- 12.3.6.1 Market Trends
- 12.3.6.2 Market Forecast
- 12.3.7 Others
- 12.3.7.1 Market Trends
- 12.3.7.2 Market Forecast
- 12.4 Latin America
- 12.4.1 Brazil
- 12.4.1.1 Market Trends
- 12.4.1.2 Market Forecast
- 12.4.2 Mexico
- 12.4.2.1 Market Trends
- 12.4.2.2 Market Forecast
- 12.4.3 Others
- 12.4.3.1 Market Trends
- 12.4.3.2 Market Forecast
- 12.5 Middle East and Africa
- 12.5.1 Market Trends
- 12.5.2 Market Breakup by Country
- 12.5.3 Market Forecast
13 SWOT Analysis
- 13.1 Overview
- 13.2 Strengths
- 13.3 Weaknesses
- 13.4 Opportunities
- 13.5 Threats
14 Value Chain Analysis
15 Porters Five Forces Analysis
- 15.1 Overview
- 15.2 Bargaining Power of Buyers
- 15.3 Bargaining Power of Suppliers
- 15.4 Degree of Competition
- 15.5 Threat of New Entrants
- 15.6 Threat of Substitutes
16 Competitive Landscape
- 16.1 Market Structure
- 16.2 Key Players
- 16.3 Profiles of Key Players
- 16.3.1 Agilent Technologies, Inc.
- 16.3.1.1 Company Overview
- 16.3.1.2 Product Portfolio
- 16.3.1.3 Financials
- 16.3.1.4 SWOT Analysis
- 16.3.2 Berry Genetics Inc.
- 16.3.2.1 Company Overview
- 16.3.2.2 Product Portfolio
- 16.3.3 BGI Genomics Co. Ltd.
- 16.3.3.1 Company Overview
- 16.3.3.2 Product Portfolio
- 16.3.3.3 Financials
- 16.3.4 Eurofins Scientific Services Limited
- 16.3.4.1 Company Overview
- 16.3.4.2 Product Portfolio
- 16.3.4.3 Financials
- 16.3.5 F. Hoffmann-La Roche Ltd
- 16.3.5.1 Company Overview
- 16.3.5.2 Product Portfolio
- 16.3.5.3 SWOT Analysis
- 16.3.6 GE Healthcare
- 16.3.6.1 Company Overview
- 16.3.6.2 Product Portfolio
- 16.3.7 Igenomix
- 16.3.7.1 Company. Overview
- 16.3.7.2 Product Portfolio
- 16.3.7.3 Financials
- 16.3.8 Illumina Inc.
- 16.3.8.1 Company Overview
- 16.3.8.2 Product Portfolio
- 16.3.8.3 Financials
- 16.3.8.4 SWOT Analysis
- 16.3.9 Laboratory Corporation
- 16.3.9.1 Company Overview
- 16.3.9.2 Product Portfolio
- 16.3.9.3 Financials
- 16.3.9.4 SWOT Analysis
- 16.3.10 Natera Inc.
- 16.3.10.1 Company Overview
- 16.3.10.2 Product Portfolio
- 16.3.10.3 Financials
- 16.3.11 Perkinelmer Inc.
- 16.3.11.1 Company Overview
- 16.3.11.2 Product Portfolio
- 16.3.11.3 Financials
- 16.3.11.4 SWOT Analysis
- 16.3.12 Thermo Fisher Scientific Inc.
- 16.3.12.1 Company Overview
- 16.3.12.2 Product Portfolio
- 16.3.12.3 Financials
- 16.3.12.4 SWOT Analysis
- 16.3.13 Yourgene Health plc
- 16.3.13.1 Company Overview
- 16.3.13.2 Product Portfolio
- 16.3.13.3 Financials
